Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2008 2
2009 1
2010 2
2012 6
2013 2
2014 3
2015 4
2016 9
2017 4
2018 3
2019 10
2020 11
2021 15
2022 16
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Jagannath S, Jackson CC, Schecter JM, Lendvai N, Sun H, Akram M, Patel N, Martin TG. Jagannath S, et al. Among authors: martin tg. Expert Opin Biol Ther. 2024 May 13. doi: 10.1080/14712598.2024.2352591. Online ahead of print. Expert Opin Biol Ther. 2024. PMID: 38738379 Review.
BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma.
Nagarajan C, Eu Jo MW, Martin TG 3rd. Nagarajan C, et al. Among authors: martin tg 3rd. Clin Lymphoma Myeloma Leuk. 2024 Mar 16:S2152-2650(24)00109-5. doi: 10.1016/j.clml.2024.03.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38643030 No abstract available.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy.
Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek SS, Cheung A, Bylsma SA, Hansen E, Wolf JL, Wong SW, Shah N, Roybal KT, Martin TG, Ye CJ, Fong L. Ledergor G, et al. Among authors: martin tg. Blood Adv. 2024 Apr 4:bloodadvances.2023012416. doi: 10.1182/bloodadvances.2023012416. Online ahead of print. Blood Adv. 2024. PMID: 38574299
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. Wadhwa A, et al. Among authors: martin tg. Clin Cancer Res. 2024 Mar 1;30(5):1009-1021. doi: 10.1158/1078-0432.CCR-23-2130. Clin Cancer Res. 2024. PMID: 38109209 Free PMC article.
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, Oriol A, Nooka AK, Rosinol L, Chari A, Karlin L, Krishnan A, Bahlis N, Popat R, Besemer B, Martínez-López J, Delforge M, Trancucci D, Pei L, Kobos R, Fastenau J, Gries KS, van de Donk NWCJ. Martin TG, et al. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):194-202. doi: 10.1016/j.clml.2023.11.001. Epub 2023 Nov 14. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38052709 Free article. Clinical Trial.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, Banerjee A, Chastain K, Perales-Puchalt A, Stephenson T, Uhlar C, Kobos R, van der Holt B, Kruyswijk S, Kuipers MT, Groen K, Vishwamitra D, Skerget S, Cortes-Selva D, Doyle M, Zaaijer HL, Zweegman S, Verona RI, van de Donk NWCJ. Frerichs KA, et al. Among authors: martin tg. Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658. Blood Adv. 2024. PMID: 38052042 Free PMC article.
102 results